|
Genscript Biotech Corporation (1548.HK) Valoración de DCF
CN | Healthcare | Biotechnology | HKSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Genscript Biotech Corporation (1548.HK) Bundle
¿Busca calcular el valor intrínseco de Genscript Biotech Corporation? Nuestra calculadora DCF (1548HK) integra datos del mundo real con características integrales de personalización, lo que le permite refinar sus pronósticos y mejorar sus estrategias de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,126.4 | 3,040.4 | 3,812.5 | 4,867.4 | 6,530.8 | 8,656.8 | 11,475.0 | 15,210.7 | 20,162.4 | 26,726.3 |
| Revenue Growth, % | 0 | 42.98 | 25.39 | 27.67 | 34.17 | 32.55 | 32.55 | 32.55 | 32.55 | 32.55 |
| EBITDA | -874.1 | -1,359.1 | -2,657.1 | -3,026.3 | -1,940.3 | -4,283.1 | -5,677.5 | -7,525.8 | -9,975.8 | -13,223.4 |
| EBITDA, % | -41.1 | -44.7 | -69.69 | -62.18 | -29.71 | -49.48 | -49.48 | -49.48 | -49.48 | -49.48 |
| Depreciation | 160.6 | 255.9 | 371.7 | 499.8 | 576.0 | 775.7 | 1,028.3 | 1,363.0 | 1,806.7 | 2,394.9 |
| Depreciation, % | 7.55 | 8.42 | 9.75 | 10.27 | 8.82 | 8.96 | 8.96 | 8.96 | 8.96 | 8.96 |
| EBIT | -1,034.6 | -1,615.0 | -3,028.8 | -3,526.1 | -2,516.3 | -5,058.9 | -6,705.8 | -8,888.8 | -11,782.5 | -15,618.3 |
| EBIT, % | -48.66 | -53.12 | -79.44 | -72.44 | -38.53 | -58.44 | -58.44 | -58.44 | -58.44 | -58.44 |
| Total Cash | 3,318.0 | 6,008.4 | 10,935.1 | 11,386.3 | 14,998.4 | 8,656.8 | 11,475.0 | 15,210.7 | 20,162.4 | 26,726.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 568.4 | 1,102.7 | 1,108.0 | 811.2 | 1,702.3 | 2,333.7 | 3,093.5 | 4,100.5 | 5,435.5 | 7,205.0 |
| Account Receivables, % | 26.73 | 36.27 | 29.06 | 16.67 | 26.07 | 26.96 | 26.96 | 26.96 | 26.96 | 26.96 |
| Inventories | 128.2 | 246.9 | 345.1 | 466.2 | 415.0 | 677.6 | 898.2 | 1,190.6 | 1,578.2 | 2,092.0 |
| Inventories, % | 6.03 | 8.12 | 9.05 | 9.58 | 6.35 | 7.83 | 7.83 | 7.83 | 7.83 | 7.83 |
| Accounts Payable | 137.1 | 181.8 | 234.7 | 433.7 | 310.8 | 558.5 | 740.3 | 981.3 | 1,300.8 | 1,724.2 |
| Accounts Payable, % | 6.45 | 5.98 | 6.16 | 8.91 | 4.76 | 6.45 | 6.45 | 6.45 | 6.45 | 6.45 |
| Capital Expenditure | -858.6 | -948.1 | -1,035.0 | -1,681.2 | -1,226.9 | -2,632.2 | -3,489.1 | -4,625.0 | -6,130.7 | -8,126.5 |
| Capital Expenditure, % | -40.38 | -31.18 | -27.15 | -34.54 | -18.79 | -30.41 | -30.41 | -30.41 | -30.41 | -30.41 |
| Tax Rate, % | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 |
| EBITAT | -882.0 | -1,174.1 | -2,100.0 | -1,853.0 | -684.5 | -3,106.5 | -4,117.8 | -5,458.3 | -7,235.2 | -9,590.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,139.5 | -2,474.6 | -2,813.9 | -2,659.7 | -2,298.1 | -5,609.4 | -7,377.1 | -9,778.7 | -12,962.2 | -17,182.0 |
| WACC, % | 9.13 | 9.04 | 9.01 | 8.89 | 8.71 | 8.95 | 8.95 | 8.95 | 8.95 | 8.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -39,311.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17,526 | |||||||||
| Terminal Value | -251,992 | |||||||||
| Present Terminal Value | -164,117 | |||||||||
| Enterprise Value | -203,428 | |||||||||
| Net Debt | -8,008 | |||||||||
| Equity Value | -195,420 | |||||||||
| Diluted Shares Outstanding, MM | 2,109 | |||||||||
| Equity Value Per Share | -92.64 |
What You Will Receive
- Authentic Genscript Financial Data: Pre-populated with Genscript's historical and forecasted data for accurate analysis.
- Completely Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Watch Genscript's intrinsic value update in real-time as you make changes.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- User-Friendly Interface: Intuitive layout and straightforward instructions suitable for all skill levels.
Key Features
- Real-Life Genscript Biotech Data: Pre-filled with Genscript’s historical financial performance and future projections.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures as needed.
- Dynamic Valuation Model: Automatically refreshes Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Testing: Develop multiple forecasting scenarios to evaluate various valuation outcomes.
- User-Friendly Design: Intuitive and organized, catering to both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Genscript Biotech Corporation’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results to inform your investment decisions.
Why Opt for This Calculator?
- User-Friendly Interface: Tailored for both novices and seasoned users.
- Flexible Assumptions: Easily adjust inputs to suit your specific analysis.
- Real-Time Updates: Watch Genscript Biotech Corporation’s valuation change instantly as you modify inputs.
- Preloaded Data: Comes equipped with Genscript Biotech’s actual financial information for swift evaluations.
- Preferred by Experts: Favored by investors and analysts for making well-informed decisions.
Who Can Benefit from This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing portfolios, particularly in the biotech sector.
- Corporate Finance Teams: Assess valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Genscript Biotech Corporation (1548HK) to your clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain a deeper understanding of how biotech firms like Genscript Biotech Corporation (1548HK) are valued in the marketplace.
Overview of the Template Contents
- Operating and Balance Sheet Data: Pre-populated historical data and forecasts for Genscript Biotech Corporation (1548HK), covering revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A specific sheet dedicated to the Weighted Average Cost of Capital (WACC), detailing parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that illustrate intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate informed analysis.
- Key Ratios: Features profitability, leverage, and efficiency ratios pertinent to Genscript Biotech Corporation (1548HK).
- Dashboard and Charts: A visual overview of valuation outputs and underlying assumptions, designed for straightforward result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.